Botulinum Neurotoxin-A Inhibits Tumor Growth in a Triple-Negative Breast Cancer Preclinical Model

Area of Science:

• Oncology
• Neuroscience
• Immunology

Background:

• Triple-negative breast cancer (TNBC) presents a significant clinical challenge with limited therapeutic options.
• Synaptic vesicle glycoprotein 2A (SV2A) is implicated in cancer progression and serves as a receptor for botulinum neurotoxin type A (BoNT/A).
• BoNT/A has demonstrated anti-proliferative effects on prostate and breast cancer cells, indicating potential therapeutic applications.

Purpose of the Study:

• To investigate the efficacy of botulinum neurotoxin type A (BoNT/A) in inhibiting tumor growth within a triple-negative breast cancer (TNBC) preclinical model.
• To evaluate the direct effects of BoNT/A on cancer cell proliferation and tumor development in vivo.
• To explore the immunomodulatory and anti-inflammatory properties of BoNT/A in the context of TNBC.

Main Methods:

• In vitro assessment of BoNT/A's effect on 4T1 breast cancer cell proliferation.
• In vivo evaluation of BoNT/A's impact on orthotopically implanted 4T1 tumors in BALB/c mice.
• Analysis of inflammatory markers, including neutrophil and monocyte counts, in response to BoNT/A treatment.

Main Results:

• BoNT/A significantly inhibited the proliferation of SV2A-expressing 4T1 breast cancer cells in vitro.
• BoNT/A treatment led to a reduction in tumor growth in the preclinical TNBC mouse model.
• BoNT/A demonstrated anti-inflammatory effects, evidenced by decreased neutrophil and monocyte populations.

Conclusions:

• Botulinum neurotoxin type A (BoNT/A) exhibits therapeutic potential against triple-negative breast cancer (TNBC) by inhibiting tumor growth and inflammation.
• The interaction between SV2A and BoNT/A represents a promising target for novel cancer therapies.
• BoNT/A may be considered a repurposed drug for treating aggressive cancers like TNBC.